Patricia M. Danzon

Affiliations: 
Health Care Management & Economics University of Pennsylvania, Philadelphia, PA, United States 
Area:
Health Care Management, General Economics
Google:
"Patricia Danzon"

Children

Sign in to add trainee
Li-Wei Chao grad student 2002 Penn
Jonathan D. Ketcham grad student 2002 Penn
Michael F. Furukawa grad student 2005 Penn
Gilbert W. Gimm grad student 2005 Penn
Nuno Sousa Pereira grad student 2006 Penn
Eric L. Keuffel grad student 2010 Penn
Andrew Mulcahy grad student 2011 Penn
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Danzon PM, Mulcahy AW, Towse AK. (2015) Pharmaceutical pricing in emerging markets: effects of income, competition, and procurement. Health Economics. 24: 238-52
Danzon PM. (2015) Pharmacy Benefit Management: Are Reporting Requirements Pro- or Anticompetitive? International Journal of the Economics of Business. 22: 245-261
Danzon PM, Epstein AJ. (2012) Effects of regulation on drug launch and pricing in interdependent markets. Advances in Health Economics and Health Services Research. 23: 35-71
Arrow KJ, Danzon PM, Gelband H, et al. (2012) The Affordable Medicines Facility--malaria: killing it slowly. Lancet. 380: 1889-90
Danzon PM. (2012) Regulation of the biopharmaceutical industry Regulation and Economics. 607-644
Danzon PM. (2012) Regulation of Price and Reimbursement for Pharmaceuticals The Oxford Handbook of the Economics of the Biopharmaceutical Industry
Danzon PM, Nicholson S. (2012) Introduction The Oxford Handbook of the Economics of the Biopharmaceutical Industry
Danzon PM, Nicholson S. (2012) The Oxford Handbook of the Economics of the Biopharmaceutical Industry The Oxford Handbook of the Economics of the Biopharmaceutical Industry. 1-624
Danzon PM. (2012) The Economics of the Biopharmaceutical Industry The Oxford Handbook of Health Economics
Danzon PM, Towse A, Mulcahy AW. (2011) Setting cost-effectiveness thresholds as a means to achieve appropriate drug prices in rich and poor countries. Health Affairs (Project Hope). 30: 1529-38
See more...